IN8bio, Inc. INAB 深 沪
等待开盘 05-22 09:30:00 美东时间
1.68
+0.110
+7.01%
华盛通- 最 高1.75
- 今 开1.54
- 成交量 10.89万股
- 最 低 1.54
- 昨 收 1.57
- 总市值 1654.31万
- 52周最高 4.17
- 市盈率 静 --
- 换手率 1.11%
- 52周最低 1.17
- 委 比 -79.53%
- 总股本 984.71万
- 历史最高 309.57
- 量 比 1.48
- 振 幅 13.38%
- 历史最低 1.31
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多IN8bio Presents New Translational Data Of Its DeltEx DRI Platform At ISCT 2026 Annual Meeting And ASGCT 2026 Annual Meeting
Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and correlates with improved survival outcomes in glioblastomaTranslational data
05-14 20:08
IN8bio Q1 EPS $(0.26) Beats $(0.69) Estimate
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.69) by 62.32 percent. This is a 87.96 percent increase over losses of $(2.16) per share from the same
05-08 04:52
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $6 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:INAB) with a Buy and maintains $6 price target.
03-13 20:01
IN8bio Promotes Kate Rochlin To President, COO, Effective Immediately
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the promotion of Kate
02-09 21:08
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Clene (NASDAQ:CLNN) stock increased by 10.0% to $7.94 during Wednesday'...
2025-12-04 05:06
IN8bio Presents Consolidated INB-200 Phase 1 And INB-400 Phase 2 Glioblastoma Data At 2025 SNO Annual Meeting
IN8bio, Inc. (the "Company") presented consolidated data, a summary of which is located below, from its investigator-sponsored Phase 1 single-center clinical trial of INB-200 and its Company-sponsored Phase 2
2025-11-25 03:53
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
IN8bio, Inc. announced the addition of The Ohio State University as a new clinical site in its Phase 1 trial for INB-100, a donor-derived allogeneic gamma-delta T cell therapy for patients with leukemias undergoing haploidentical stem cell transplantation. This expansion aims to accelerate enrollment and evaluate INB-100's safety, durability, and anti-leukemic activity post-transplant, with promising long-term remission data already observed.
2025-10-29 12:00
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
INB-619 demonstrated equivalent efficacy to FDA-approved T Cell Engagers (TCE) for B cell depletion with minimal cytokine release, highlighting safer deep B cell depletion. It is the first pan-gamma delta T cell engager designed to expand multiple gamma delta T cell subsets for efficient target elimination. INB-619 achieved robust gamma delta T cell expansion and complete B cell depletion in both healthy donor and SLE samples. Unlike conventional...
2025-10-27 12:00
IN8bio Q2 EPS $(1.24) Beats $(1.70) Estimate
IN8bio (NASDAQ:INAB) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.70) by 27.06 percent. This is a 78.25 percent increase over losses of $(5.70) per share from the same
2025-08-08 04:08
